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Abstract
Background: The GNB3 C825T polymorphism is associated with increased G protein-mediated signal transduction,
SDF-1a-mediated lymphocyte chemotaxis, accelerated HIV-1 progression, and altered responses to antiretroviral
therapy among Caucasian subjects. The GNB3 825T allele is highly prevalent in African populations, and as such
any impact on HIV-1 acquisition or progression rates could have a dramatic impact. This study examines the
association of the 825T polymorphism with HIV-1 acquisition, disease progression and immune activation in two
African cohorts. GNB3 825 genotyping was performed for enrolees in both a commercial sex worker cohort and a
perinatal HIV transmission (PHT) cohort in Nairobi, Kenya. Ex vivo immune activation was quantified by flow
cytometry, and plasma chemokine levels were assessed by cytokine bead array.
Results: GNB3 genotype was not associated with sexual or vertical HIV-1 acquisition within these cohorts. Within
the Pumwani cohort, GNB3 genotype did not affect HIV-1 disease progression among seroconverters or among
HIV-1-positive individuals after adjustment for baseline CD4 count. Maternal CD4 decline and viral load increase in
the PHT cohort did not differ between genotypes. Multi-parametric flow cytometry assessment of T cell activation
(CD69, HLA-DR, CD38) and Treg frequency (CD25
+FOXP3
+) found no differences between genotype groups. Plasma
SDF-1a, MIP-1b and TRAIL levels quantified by cytokine bead array were also similar between groups.
Conclusions: In contrast to previous reports, we were unable to provide evidence to suggest that the GNB3 C825T
polymorphism affects HIV-1 acquisition or disease progression within African populations. Ex vivo immune
activation and plasma chemokine levels were similarly unaffected by GNB3 genotype in both HIV-1-negative and
HIV-1-positive individuals. The paucity of studies investigating the impact of GNB3 polymorphism among African
populations and the lack of mechanistic studies make it difficult to assess the true biological significance of this
polymorphism in HIV-1 infection.
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Background
Previously regarded as dispensable in HIV-1 pathogenesis,
the G protein-mediated signaling cascades initiated by
chemokine receptors including CCR5 and CXCR4 are
now being shown to play important roles in HIV entry,
viral latency and disease progression [1-3]. The gp120-co-
receptor interaction activates unique signal transduction
events that remove blocks to replication, and signaling
through other chemokine receptors (including CCR6 and
CCR7) during HIV-1 infection may also influence patho-
genesis [2,3]. Induction of lymphocyte chemotaxis to sites
of viral replication may promote immune activation,
which is known to be a driver of HIV disease progression
[3,4]. The majority of signaling events initiated by chemo-
kine receptors are mediated by heterotrimeric G proteins
comprised of an alpha, beta and gamma subunit, each of
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any medium, provided the original work is properly cited.which is expressed in multiple isoforms. One beta subunit-
encoding gene, guanine nucleotide binding protein beta
polypeptide 3 (GNB3), harbours a single nucleotide poly-
morphism (SNP) at position 825 (rs5443) that has been
widely associated with a number of health outcomes,
including predisposition to diabetes, obesity, hypertension
and atherosclerosis [5] (reviewed in [6]). Compared to
other chronic diseases, few studies have examined the
impact of the GNB3 SNP on immune function and sus-
ceptibility to infectious diseases, particularly HIV. Intrigu-
ingly, however, one report suggests that GNB3 825TT
genotype is associated with accelerated HIV-1 disease pro-
gression in a Caucasian cohort, and the same group also
reported improved virologic responses to HAART among
HIV-1-positive 825TT patients compared to CC and CT
genotypes [7,8]. To date, no data are available to support
or oppose these associations in additional cohorts, and it
is still unknown whether GNB3 genotype also influences
susceptibility to HIV-1 infection.
Within African populations, where the worldwide HIV
burden is highest, an effect of GNB3 825 genotype on
HIV-1 disease progression and treatment outcome could
have a dramatic impact, as the 825T allele frequency is
high (80%) compared to Caucasian populations (~20%)
[9]. Despite the extensive number of publications describ-
ing associations between GNB3 and diseases in Caucasian
and Oriental populations, reviews and meta analyses high-
light the difficulty of drawing firm conclusions from small
sample sizes [10-12] and also emphasize the population-
specific nature of many of these associations and the
paucity of GNB3 epidemiological studies in African popu-
lations [10-14]. In many cases, genetic association studies
have not been followed up with functional experiments
designed to directly assess the impact of the GNB3 C825T
S N Po nh e a l t ho u t c o m e s .
The impact of the GNB3 825 SNP on both HIV-1 acqui-
sition and disease progression within African populations
is also of particular interest in light of our recent report
that a SNP in the CD4 gene (CD4 C868T, rs28919570),
located in close proximity to GNB3 on chromosome 12, is
associated with increased risk of HIV-1 acquisition in a
high-risk Kenyan cohort and a mother-to-child HIV-1
transmission cohort [15,16]. Despite functional data indi-
cating that the amino acid change caused by the 868T
substitution results in altered CD4-gp120 affinity, it could
not be ruled out that linkage with the GNB3 SNP was con-
tributing to the observed epidemiological association
between CD4 868T and HIV-1 acquisition.
Although the precise mechanism of action of the GNB3
SNP remains unclear, it is generally accepted that the pre-
sence of the 825T allele results in increased G protein-
mediated signaling in numerous cell types, including
immune cells [5,17]. Notably, several studies have indi-
cated that the 825T allele can mediate increased
chemotaxis of human T cells [18], and in healthy Cauca-
sians the allele is also associated with increased CD4 T cell
counts, proliferative responses to recall antigens and
decreased lymphocyte apoptosis [14,19,20]. This has led
some to suggest that the 825T allele is predictive of immu-
nocompetence [19,20]. Together, these data suggest intri-
guing ways in which the 825TT genotype may affect
HIV-1 acquisition and disease progression, either by alter-
ing signaling pathways required for HIV replication and/
or through modulation of immune activation and antigen-
specific cellular immune responses.
Given the reports linking GNB3 825T to accelerated
disease progression in Caucasians, the evidence demon-
strating the role of G protein signaling in establishing
HIV infection and the possibility of linkage disequili-
brium between the CD4 and GNB3 SNPs, we sought to
characterize the impact of the GNB3 SNP in two African
cohorts: a high-risk commercial sex worker (CSW)
cohort and a low-risk perinatal HIV transmission (PHT)
cohort, both located in Nairobi, Kenya. We also assessed
the impact of the GNB3 genotype on T cell activation in
both healthy and HIV-1-positive patients as well as
plasma levels of the CXCR4 ligand SDF-1a, CCR5 ligand
MIP-1b and apoptosis-inducing protein, TRAIL.
Results
Linkage disequilibrium between CD4 868T and GNB3 825T
The GNB3 C825T SNP was found at a frequency of
79.9% in 1031 members of the CSW cohort and 68.9%
among 395 mothers in the PHT cohort, consistent with
available African population data [9]. In both HIV-1-
negative and HIV-1-positive groups, the GNB3 825 gen-
otypes of the CSW cohort were in Hardy-Weinberg
equilibrium (Table 1). Analysis of linkage disequilibrium
in the CSW cohort using a LOD score cutoff threshold
of 2.0 found that GNB3 825T was not significantly
linked to CD4 868T (LOD = 1.14, D’ = 0.338, r
2 =
0.0060).
Association of GNB3 825T with HIV-1 acquisition and
transmission
No epidemiological analysis of GNB3 825T and risk of
HIV-1 seroconversion has been previously reported. Survi-
val analysis of the time from enrolment to seroconversion
among participants of the CSW cohort did not signifi-
cantly differ between CC/CT and TT genotypes [Cox pro-
portional hazard analysis, Hazard Ratio (HR) 1.313, 95%
CI 0.910, 1.895, p = 0.15] (Figure 1). Inclusion of the CD4
868 genotype in the seroconversion hazard model did not
demonstrate any significant interaction between GNB3
and CD4 genotype. Consistent with these data, there were
no differences in GNB3 genotype frequency between HIV-
1-negative and HIV-1-positive CSW participants [p = 0.19,
chi squared] (Table 1).
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maternal HIV-1 transmission rates either in utero, peripar-
tum or via breastmilk in a low-risk Kenyan perinatal HIV
transmission cohort (PHT) for which both viral load and
CD4 count data were available. The overall risk of
mother-to-child transmission was not associated with
infant GNB3 genotype in an unadjusted model [HR 1.23,
95% CI: 0.76, 1.98, p = 0.40] or following adjustment for
maternal viral load [p = 0.51]. Subgroup analysis of in
utero, peripartum and breastmilk transmission events
revealed no effect of 825 genotype on in utero transmis-
sion [Odds ratio(OR) 0.89, 95% CI: 0.38, 2.07, p = 0.78
unadjusted; OR 1.00, 95% CI 0.41, 2.44, p = 1.00 adjusted
for maternal viral load] or peripartum transmission [OR
0.94, 95% CI 0.47, 1.87, p = 0.85 unadjusted; OR 0.84, 95%
CI 0.40, 1.73, p = 0.63 adjusted], but did show a trend
toward an increased risk of breastmilk transmission in the
TT genotype group [OR 8.35, 95% CI 1.09, 64.13, p = 0.04
unadjusted; OR 7.41, 95% CI 0.94, 58.2, p = 0.06 adjusted].
This was not accompanied by a significant difference in
maternal breastmilk viral load either between CC/CT and
TT infants or between CC/CT and TT mothers [p = 0.54]
(data not shown).
Association of GNB3 825T with HIV-1 Disease progression
Given that Caucasian HIV-1-positive patients with the
GNB3 825TT genotype were reported to exhibit acceler-
ated disease progression and to respond more favourably
to HAART than CC or CT genotypes [7,8], we assessed
HIV disease progression in both the CSW and MCH
cohorts. Within the CSW cohort, 73 genotyped partici-
pants seroconverted after their enrolment and returned for
at least one follow-up visit. Among those participants, sur-
vival analysis of time to CD4 counts of < 350 cells/uL did
not show any significant effect of the GNB3 825 genotype,
nor was there any interaction with the CD4 868 genotype
[HR 0.665, 95% CI 0.369, 1.198, p = 0.1742] (Figure 2a).
Given the relatively small sample size of seroconverter
patients, we also analysed disease progression among 146
women who were HIV+ with CD4 counts > 500 at the
time of recruitment. Because the seroconversion dates for
Table 1 GNB3 C825T genotype frequency for HIV-1
negative and HIV-1 positive individuals in the CSW
cohort
GNB3 825 Genotype HIV-1 Negative
(n = 349)
HIV-1 Positive
(n = 682)
CC (homozygous
wildtype)
15 (4.3%) 27 (4.0%)
CT (heterozygous) 124 (35.5%) 206 (30.2%)
TT (homozygous
variant)
210 (60.2%) 449 (65.8%)
CT Frequency 0.355 0.302
P for HWE 0.904 0.942
C allele
T allele
0.22
0.78
0.19
0.81
Note: Data are no. (%) of subjects, unless otherwise indicated. For the
comparison between HIV-1-negative and HIV-1-positive subjects, p = 0.19 (chi
squared test). HWE, Hardy-Weinberg equilibrium
Figure 1 Kaplan-Meier survival analysis of time from enrolment to seroconversion in Pumwani cohort participants. 277 individuals with
a known date of seroconversion were included in this analysis: 99 GNB3 825CC/CT and 178 GNB3 825TT. There was no difference in time to
seroconversion as determined by Cox proportional hazard regression [Hazard Ratio (HR) 1.313, 95% CI 0.910, 1.895, p = 0.15]. Icons between
drops in the lines represent the end of an individual’s data set (censoring event).
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Figure 2 Kaplan-Meier survival analysis of HIV disease progression to CD4 count < 350 cells/uL among. (A) 73 CSW cohort participants
who seroconverted during follow-up: 21 GNB3 825CC/CT subjects and 52 GNB3 825TT subjects. There were no significant differences in time to
CD4 < 350 as determined by Cox proportional hazard analysis [HR 0.665, 95% CI 0.369, 1.198, p = 0.1742]. (B) 146 HIV-1-positive CSW cohort
subjects: 48 GNB3 825CC/CT subjects and 98 GNB3 825TT subjects. Following adjustment for baseline CD4 count, there were no significant
differences in time to CD4 < 350 as determined by Cox proportional hazard analysis [HR = 0.956, 95% CI 0.619, 1.477, p = 0.8397]. (C) 262 PHT
cohort HIV-1-positive mothers: 125 GNB3 825CC/CT subjects and 137 GNB3 825TT subjects. Following adjustment for baseline CD4 count, there
were no significant differences in time to CD4 < 350 as determined by Cox proportional hazard analysis [HR = 0.75, 95% CI 0.47, 1.19, p = 0.22].
Juno et al. Retrovirology 2012, 9:1
http://www.retrovirology.com/content/9/1/1
Page 4 of 12these women were not known, the time to CD4 < 350
cells/uL and CD4 < 250 cells/uL was adjusted for baseline
CD4 count. After adjustment, there was no significant dif-
ference in time to progression in 825 CC/CT patients com-
pared to 825 TT patients, nor was there any interaction
with CD4 genotype [CD4 < 350: HR = 0.956, 95% CI 0.619,
1.477, p = 0.8397; CD4 < 250: HR = 0.966, 95% CI 0.594,
1.570, p = 0.8879] (Figure 2b).
Although infant HIV-1 progression data were not
available for the transmission events in the PHT cohort,
maternal data regarding progression to CD4 < 350 cells/
uL, monthly rate of CD4 decline, death and viral load
were available. CD4 decline to < 350 cells/uL did not
significantly differ between 825TT and 825CC/CT geno-
types before or after adjustment for baseline CD4 count
[HR = 0.75, 95% CI 0.47, 1.19, p = 0.22 adjusted] (Figure
2c). Overall risk of death was not affected by GNB3 gen-
otype [HR = 1.94, 95% CI 0.46, 8.18, p = 0.36]. Linear
mixed modeling analysis of CD4 loss over two years of
f o l l o w - u pd e m o n s t r a t e dat r e n dt o w a r ds l o w e rC D 4
decline among 825TT genotype mothers, although the
difference was only an average of 2.82 cells per month
(9.46 cells/month among 825 CC/CT versus 6.64 cells/
month among 825TT) [p = 0.08]. Similar modeling of
viral load change over time did not reveal any significant
effect of GNB3 genotype on viral load increase [p = 0.5]
(not shown).
Differences in Immune Activation Associated with GNB3
Genotype
The potential for GNB3 genotype to influence lympho-
cyte chemotaxis, cellular activation, apoptotic pathways
and CD4 counts [18] could have important implications
for HIV-1 disease progression, which can be driven by
increasing immune activation and apoptosis [4]. The
only data available describing T cell immune activation
in subjects with varying GNB3 g e n o t y p e si sr e p o r t e di n
an assessment of healthy Caucasian individuals [20]. No
differences in HLA DR expression on T cells were
observed, and although bulk CD4 counts were shown to
be increased in Caucasian subjects, the study did not
measure any CD4+ T cell subsets such as regulatory T
cells (Tregs). Therefore, to determine the effect in a
genetically distinct population we assessed the ex vivo
expression of CD69, HLA-DR and CD38, and the pro-
portion of Tregs in both healthy and HIV-1-positive
women from the Kenyan CSW cohort. In healthy
women, no differences in expression of CD69 (acute
activation), HLA-DR or CD38 (chronic activation) were
observed between CC/CT and TT genotypes on either
CD4+ or CD8+ T cells [Mann-Whitney test, p > 0.1 for
all]. Expression patterns of HLA-DR and CD38 were
confirmed to be similar in a second cross-sectional
study [Mann-Whitney test, p > 0.1 for all] (Figure 3a).
We also found no differences in Treg frequency,
expressed as a percentage of CD4+ T cells [Mann-Whit-
ney test, p = 0.96] (Figure 3a). Although activated CD4+
T cells are generally considered to be prime targets for
HIV-1 infection and replication, cellular susceptibility to
HIV-1 infection requires the expression of either the
CCR5 (in early infection) or CXCR4 (in late infection)
co-receptor. To more specifically characterize T cell sus-
ceptibility to infection, we compared the percentage of
cells expressing either CXCR4 or CCR5 between GNB3
genotypes, but found no differences between 825 CC/
CT and TT groups [Mann-Whitney test, p > 0.1 for
both] (Figure 3b). As most infecting viruses utilize the
CCR5 co-receptor, we also compared the density of
CCR5 expression on CD4+ T cells (as measured by
median fluorescence intensity) (Figure 3b) and the acti-
vation state of CD4+CCR5+ cells (as measured by CD69
and HLA DR expression) (Figure 3c). No differences in
any of these parameters were observed between geno-
type groups [Mann-Whitney test, p > 0.1 for all].
In HIV+ women, expression of CD69, HLA-DR and
CD38 did not differ between GNB3 genotype groups on
either CD4+ or CD8+ T cells, before or after adjustment
for CD4 count [Mann-Whitney test, p > 0.1 for all;
ANCOVA with CD4 count as covariate, p > 0.1 for all]
(Figure 4). Comparison of HLA-DR expression between
genotypes was replicated in 4 cross-sectional studies, and
CD38 expression was assessed in 3 replicate studies.
Additionally, we measured expression of IL-7Ra (CD127)
and Fas (CD95), both known correlates of HIV-1 disease
progression [21,22]. Expression of both markers did not
differ between GNB3 genotypes, either before or after
adjustment for CD4 count [Mann-Whitney and
ANCOVA, p > 0.1 for all] (Figure 4). Finally, the propor-
tion of Tregs expressed as a percentage of CD3+ cells
was also similar between genotype groups [Mann-Whit-
ney test, p = 0.91] (not shown).
Plasma SDF-1a, MIP-1b and TRAIL Quantification
To complement the cell surface marker data, we assessed
plasma concentrations of three cytokines/chemokines of
interest: SDF-1a,M I P - 1 b and TRAIL. Given that 825TT
patients are known to exhibit enhanced SDF-1a-
mediated chemotaxis, we wondered whether plasma che-
mokine levels might vary between GNB3 genotype during
infection. Additionally, some evidence points to lower
levels of lymphocyte apoptosis in 825TT patients, leading
us to assess plasma levels of the cleaved form of TNF-
related apoptosis-inducing ligand (TRAIL, CD253).
There were no significant differences in plasma TRAIL,
SDF-1a or MIP-1b levels between CC/CT and TT geno-
types [Mann-Whitney, p = 0.31, p = 0.14 and p = 0.88
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treatment status did not reveal any further differences in
protein concentration between genotypes (not shown).
Discussion
This study assesses the impact of the GNB3 825 SNP on
HIV-1 acquisition and disease progression in two Ken-
yan cohorts: a cohort of female commercial sex workers
CD4+ T Cells 
CD8+ T Cells 
CD69 
CD69 
CD38  HLA DR  Treg 
CD38 HLA  DR 
A) 
B)  CD4+ T Cells 
C)  CD4+CCR5+ T Cells 
CXCR4 CCR5  CCR5  MFI 
CD69 HLA  DR 
Figure 3 Expression of ex vivo cell surface markers measured by flow cytometry among HIV-1-negative subjects. (A) Expression of
CD69, HLA-DR, CD38 and regulatory T cells (Tregs; defined as CD3+CD4+CD25+FOXP3+) among HIV-1-negative CSW cohort subjects. Values are
expressed as a percentage of the parental CD4+ or CD8+ T cell population, as indicated. CD38 and HLA-DR plots are representative of two
distinct studies. There were no significant differences in expression levels between GNB3 825CC/CT and 825TT groups as measured by Mann-
Whitney test [p > 0.1 for all]. (B) Expression of HIV-1 co-receptors CCR5 and CXCR4 expressed as a percentage of the parental CD4+ T cell
population. There were no significant differences in expression levels or CCR5 median fluorescence intensity (MFI) between GNB3 825CC/CT and
825TT groups as measured by Mann-Whitney test [p > 0.1 for all]. (C) Expression of activation markers CD69 and HLA DR on CD4+CCR5+ T cells.
There were no significant differences in expression levels between GNB3 825CC/CT and 825TT groups as measured by Mann-Whitney test [p >
0.1 for all].
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CSW cohort), and a low-risk perinatal HIV transmission
cohort (PHT cohort). Given the data indicating popula-
tion-specific effects of the 825T allele and the high T
allele frequency in African compared to Caucasian
populations (80% versus 20%, respectively), it is impor-
tant to understand the effect of the SNP in a population
of high HIV-1 prevalence [9]. The effect of the SNP in
A) CD4+ T Cells 
B) CD8+ T Cells 
HLA DR 
HLA DR 
CD38 
CD38 
CD69 
CD69 
Fas (CD95) 
Fas (CD95) 
IL7RD (CD127) 
IL7RD (CD127) 
Figure 4 Expression of ex vivo cell surface markers among HIV-1-positive subjects. Expression of IL-7Ra, Fas, CD69, HLA-DR, and CD38 was
among HIV-1-positive CSW cohort participants. Values are expressed as a percentage of the parental (A) CD4+ or (B) CD8+ T cell population, as
indicated. CD69 plots are representative of two distinct studies, CD38 plots represent three distinct studies and HLA-DR plots represent four
distinct studies. There were no significant differences in expression levels between GNB3 825CC/CT and 825TT groups as measured by Mann-
Whitney test [p > 0.1 for all].
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viously reported that a SNP in the CD4 gene, CD4
C868T, is associated with increased risk of HIV-1 acqui-
sition in this cohort. The CD4 and GNB3 genes are
located in close proximity on chromosome 12, and may
contain SNPs in linkage disequilibrium. We, therefore,
wondered whether the GNB3 825T allele might contri-
bute to the epidemiological effects attributed to the CD4
SNP, but no significant linkage was found between the
GNB3 825T and CD4 868T alleles.
Given recent evidence suggesting an important role for
G protein signaling in promoting HIV-1 replication and
entry into resting T cells, and the fact that the GNB3
C825T SNP is one of the most commonly described poly-
morphisms in human G protein subunit genes [1,3,23], it
is important to attempt to replicate previously reported
associations of the 825T allele with accelerated HIV-1
disease progression and HAART responses [7,8]. The
association of the 825TT genotype with increased risk of
HIV-1 progression, however, is somewhat at odds with
other reports suggesting a protective effect of the T allele
in infection. GNB3 825T is associated with improved cel-
lular responses to Hepatitis B vaccination, and the 825CC
genotype may confer a poor response to interferon a/riba-
virin therapy in Hepatitis C infection as well as increased
risk of infant death due to infection [19,24,25]. Given that
epidemiological studies linking the 825T allele to non-
infectious diseases have found evidence of population-spe-
cific effects with little functional data to demonstrate the
mechanisms of action of the T allele, it is important to
confirm the associations between GNB3 825T and HIV-1
progression, as well as to better understand the impact of
the SNP on immune function during chronic disease.
Surprisingly, we were unable to demonstrate any effect
of the GNB3 825T allele on HIV-1 acquisition or disease
progression in either cohort. Although there was a trend
toward increased risk of infant HIV-1 acquisition via
breastmilk transmission (p = 0.06 adjusted for maternal
viral load), this reflected a total of 16 transmission events
(the least frequent mode of mother-to-child transmission
observed in this cohort) and was not accompanied by a
difference in maternal breastmilk viral load. The lack of
association with either sexual or vertical HIV-1 transmis-
sion did not appear to be due to any confounding effect of
the CD4 868 SNP. To date, there have been no reports of
increased HIV-1 acquisition associated with GNB3 geno-
type in any population. Our analysis also failed to confirm
the previously reported observation that the GNB3 825TT
genotype is associated with increased HIV-1 disease pro-
gression as measured by CD4 decline [7]. Regardless of
whether analysis was limited to patients followed from the
time of seroconversion, or included HIV-1-positive partici-
pants with unknown seroconversion dates (with adjust-
ment for baseline CD4 count), and whether disease
TRAIL  SDF-1D
MIP-1E
Figure 5 Quantification of plasma cytokine/chemokine levels. Plasma SDF-1a, MIP-1b and TRAIL concentrations were quantified by Milliplex
bead assay among HIV-1-positive women of the CSW cohort. No significant differences in concentration between GNB3 825CC/CT and 825TT
groups were detected by Mann-Whitney test [p = 0.14 for SDF-1a, p = 0.88 for MIP-1b, p = 0.31 for TRAIL].
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250 and/or death, rate of CD4 decline or viral load
increase over time, there was no association between
GNB3 genotype and HIV-1 disease progression. A small
subset of HIV-1-positive GNB3 genotyped patients from
the CSW cohort for whom ARV initiation and CD4 count
data were available were included in a survival analysis of
time to CD4 rebound to > 300 cells/uL following ARV
initiation. Among this group (n = 12 CC/CT, 17 TT),
there was also no difference in response to ARV therapy
(data not shown).
Given the high 825T allele frequency among African
populations, it was important to determine whether GNB3
genotype would affect disease progression similarly to the
reported effect in a study of Caucasian participants. The
absence of a GNB3 effect on disease progression in this
study does not necessarily imply that GNB3 genotype does
not affect HIV progression in other ethnic populations;
rather, it underscores the importance of replicating genetic
association studies in populations with disparate allele fre-
quencies. Furthermore, it cannot be ruled out that differ-
ence of cohort gender composition between this and
previous studies contributed to the contrasting results.
Studies of the GNB3 825 SNP in African populations are
lacking in the literature, but our results, along with others
[26], suggest that phenotypes associated with the 825T
allele may not be detected in African populations, and
reinforce the observation that more diverse studies are
required. Another gap within the body of GNB3 literature
lies in the lack of functional studies to accompany epide-
miological analyses. Although the C to T mutation does
not affect the amino acid sequence of the Gb3 protein, it
is associated with the production of truncated splice var-
iants, Gb3s and Gb3s2 [5,17]. Biochemical characterization
of these transcripts suggests that they are biologically
active, and promote increased signaling activity following
G protein coupled receptor activation. However, data
demonstrating Gb3s/s2 expression at the protein level in
vivo are still lacking [5,27].
Given the documented effect of enhanced lymphocyte
chemotaxis in healthy Caucasian 825T allele carriers [18]
and the potential impact of the splice variants on immune
signaling pathways, we assessed the impact of GNB3 geno-
type on cellular immune activation and plasma cytokine/
chemokine levels in healthy and HIV-1-positive CSW
cohort participants. No differences in acute or chronic
activation marker expression (CD69, HLA-DR and CD38)
on either CD4+ or CD8+ T cells were observed in HIV-1-
negative participants, confirming and extending a previous
report that HLA-DR expression was not altered across
GNB3 genotypes in healthy Caucasians [20]. The same
study also indicated that healthy Caucasian 825T allele
carriers have increased CD4+ T cell counts (with no
differences in B cell or CD8+ T cell counts), but did not
assess the proportion of any CD4+ T cell subpopulations
such as Tregs [20]. In the current study, we did not
observe any differences in Treg proportion between GNB3
825CC/CT and TT participants.
Analyses among HIV-1-positive patients also failed to
identify any differences in ex vivo immune activation as
m e a s u r e db yC D 6 9 ,H L A - D R ,o rC D 3 8 .T oo u rk n o w l -
edge, this is the first study to quantify activation markers
among HIV-1-positive patients with respect to GNB3 gen-
otype. We also measured expression of IL-7Ra (CD127)
and Fas (CD95), two known correlates of disease progres-
sion. During HIV infection, IL-7Ra inversely correlates
with immune activation and apoptosis, and positively cor-
relates with CD4 count [22], while Fas expression posi-
tively correlates with disease progression [21,28]. Neither
marker was differentially expressed on CD4+ or CD8+ T
cells between GNB3 genotypes. Given the limitations of
cross-sectional studies in assessing differences between
markers correlated with disease progression, we analysed
all surface marker expression with adjustment for CD4
count, but still observed no differences between GNB3
genotypes. GNB3 825T allele carriers demonstrate
increased SDF-1a-mediated lymphocyte chemotaxis [18]
(a process mediated by G protein signaling); therefore, we
wondered whether CXCR4 ligand SDF-1a or CCR5 ligand
MIP-1b would be differently expressed between GNB3
genotypes, particularly during HIV-1 infection. Plasma
TRAIL levels were also assessed due to the previously
reported observation of decreased lymphocyte apoptosis
among 825TT individuals [14]. Consistent with the cell
surface marker data, SDF-1a,M I P - 1 b and TRAIL levels
were also similar between CC/CT and TT genotypes.
While these results do not assess the impact of the GNB3
splice variants on intracellular signaling pathways nor
imply that there is no impact of the 825 SNP on signal
transduction, our data do suggest that GNB3 genotype
does not have a substantial impact on co-receptor expres-
sion or the activation of bulk or CD4+CCR5+ T cells.
Investigation of these markers in cohorts that do exhibit
an impact of GNB3 genotype on HIV-1 progression may
provide further information about the mediators of the
rate of progression.
Conclusions
Overall, our data indicate that the GNB3 C825T SNP
does not play a significant role in HIV-1 acquisition, dis-
ease progression or immune activation in the African
cohorts described. Given the population-specific effects
of the GNB3 825 S N P ,f u r t h e rd a t aw i l lb er e q u i r e dt o
conclusively determine what role it may play in HIV-1
progression in non-African populations, and to more
fully describe its mechanism of action.
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Subjects
Pumwani Commercial Sex Worker Cohort
This retrospective study was performed in the Pumwani
Commercial Sex Worker (CSW) cohort in Nairobi, Kenya
which is an open cohort of female commercial sex workers
who are highly exposed to HIV-1. The study was approved
by the ethics review boards of both the Kenyatta National
Hospital and the University of Manitoba. Participants in
the cohort report for follow-up twice a year, when blood
samples are taken for HIV-1 serology and CD4+ T cell
count determination. GNB3 genotypes of 1031 partici-
pants were analysed for allele frequency and Hardy-Wein-
berg equilibrium, 969 of which were assessed for linkage
disequilibrium with the CD4 C868T SNP. Analyses of
time to HIV acquisition and disease progression were
restricted to patients with complete follow-up data, result-
ing in a sample group of 204 HIV- and 219 HIV+ patients
(73 of whom seroconverted during their follow-up in the
cohort).
Perinatal HIV Transmission (PHT) Cohort
This cohort recruited HIV+ pregnant women from
antenatal clinics in Nairobi, Kenya to investigate factors
affecting in utero, postpartum and breastmilk HIV trans-
mission. The study was approved by the ethics review
boards of Kenyatta National Hospital, the University of
Manitoba and the University of Washington. Participants
were enrolled at 32 weeks gestation and began taking zido-
vudine twice a day from 34-46 weeks of pregnancy and
following through delivery, as per Kenyan guidelines [29].
Women visited the clinic antenatally, at delivery, 2 weeks
after birth and monthly for 12 to 24 months. Blood speci-
mens were collected at months 1, 3, 6, 9, 12, 18 and 24 fol-
lowing delivery for CD4+ T cell count and HIV viral load
(VL) determination. GNB3 genotype was determined for
the 444 mothers and 395 children who were included in
this study.
DNA Isolation
CSW cohort DNA samples were isolated either from
whole blood, peripheral blood mononucleocytes (PBMCs),
or B cell lines using Qiagen DNA extraction kits or Qiagen
BioRobot EZ1 (Qiagen, Inc., Mississauga, ON, Canada)
following the manufacturer’s instructions. DNA was iso-
lated from PHT cohort maternal serum samples using the
QiaAmp DNA Mini Kit serum protocol (Qiagen, Inc.,
Mississauga, ON, Canada), as described in the manufac-
turer protocol. DNA from infant bloodspots was isolated
using the QiaAmp DNA Mini Kit dried bloodspot proto-
col as described.
PCR and Sequence Analysis
Nested PCR amplification of the GNB3 825T locus was
performed with the outer primer set (Table 2) at an
annealing temperature of 60°C. 2 μlo ft h er e a c t i o nw a s
added as template for the nested reaction using the
inner primer set (Table 2) at an annealing temperature
of 60°C. Sequencing was performed in both directions
using either the forward or reverse sequencing primers.
Sequences were resolved on an ABI3100 sequencer, and
genotyped by visual inspection using Sequencher and
Codon Express software.
Viral Load Determination
HIV-1 RNA VL was quantified in plasma using the Gen-
Probe Transcription Mediated Amplification assay, which
is sensitive for detection of Kenyan HIV-1 subtypes A, C,
and D (Gen-Probe Incorporated, San Diego, CA) [30].
Multi-parametric Flow Cytometry
Peripheral blood mononuclear cells (PBMC) were iso-
lated from fresh blood samples by layering onto ficoll-
hypaque (Bio-Lynx). PBMC were immediately stained
following isolation with flurochrome-conjugated antibo-
dies specific to CD3, CD4, CD8, CD69, HLA-DR, CD38,
IL-7Ra (CD127) and Fas (CD95) (BD Biosciences). Reg-
ulatory T cells were identified by expression of CD3,
CD4, CD25 (BD Biosciences) and intracellular staining
of FOXP3 (eBiosciences) according to manufacturer’s
instructions [31]. Data were collected on the BD LSRII
using FACS Diva software, and analysed with FlowJo
version 7.2.
Plasma chemokine quantification
Plasma concentrations of SDF-1a,M I P - 1 b and TRAIL
were quantified using the Milliplex Human Cytokine/
Chemokine and Human Cytokine/Chemokine Panel II
kits (Millipore) as per the manufacturer’s short protocol.
The assay was run on the BioRad Bio-Plex 200 and ana-
lysed with Bioplex Manager Software v5.0.
Table 2 Primers used in PCR amplification and sequencing of GNB3 C825T SNP
Primer Set Forward Primer (5’ -3 ’) Reverse Primer (5’-3’)T a (
°C)
Outer GCTGCCCAGGTCTGATCCCT CCAGTGACAAGGGACAGCAGTAAG 60
Inner TGACCCACTTGCCACCCGTGC GCAGCAGCCAGGGCTGGC 60
Sequencing CAGTTCTTCCCCAATGGAGAGG GGCTGGCCCTTACCCACACG 55
Ta: annealing temperature.
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A total of 969 Pumwani CSWs were genotyped for both
CD4 868 (rs28919570) and GNB3 825 (rs5443). The
extent of linkage disequilibrium between these two
SNPs (LOD score, D’, and r
2) was determined with Hap-
loview version 4.2. Cox proportional hazard regression
and Kaplan-Meier survival analysis were used to deter-
mine the association of GNB3 genotype with time to
HIV acquisition and time to disease progression defined
by time to CD4 < 350, CD4 < 250 and death. Linear
mixed effect models were used to determine associations
between GNB3 genotype and the rate of change in CD4
count and viral load over time. Linear regression was
used to compare baseline CD4 count and log10 trans-
formed plasma viral load among mothers. All analyses
were specific ap r i o r iand data were analysed in SAS
and SATA version 11 (College Station TX). Comparison
of immune activation markers and plasma cytokine/che-
mokine concentrations was performed by non-para-
metric Mann-Whitney tests in GraphPad Prism version
4, and analysis of co-variance (ANCOVA) in SPSS ver-
sion 16. P values were considered significant at p < 0.05.
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